Sionna Therapeutics (NASDAQ:SION) Stock Price Down 4.5% – Time to Sell?

Posted by Francis Steltz on Jul 22nd, 2026

Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report) dropped 4.5% during mid-day trading on Monday . The company traded as low as $47.53 and last traded at $47.1790. 37,710 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 379,349 shares. The stock had previously closed at $49.41.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Stifel Nicolaus raised their target price on shares of Sionna Therapeutics from $44.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, May 18th. Wall Street Zen cut Sionna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Freedom Capital downgraded Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Finally, Wedbush initiated coverage on Sionna Therapeutics in a report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $53.22.

View Our Latest Analysis on Sionna Therapeutics

Sionna Therapeutics Stock Up 3.3%

The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of -24.46 and a beta of 1.33. The business’s 50 day simple moving average is $40.86 and its 200-day simple moving average is $39.69.

Sionna Therapeutics (NASDAQ:SION – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.08). On average, analysts expect that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Insider Activity at Sionna Therapeutics

In other Sionna Therapeutics news, Director Peter A. Thompson sold 184,639 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares in the company, valued at $123,491,612.84. This represents a 6.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 184,639 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares in the company, valued at approximately $123,491,612.84. This represents a 6.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 989,630 shares of company stock valued at $44,987,483. Company insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its stake in Sionna Therapeutics by 16.8% during the first quarter. Bank of America Corp DE now owns 50,870 shares of the company’s stock worth $2,039,000 after acquiring an additional 7,303 shares in the last quarter. Stempoint Capital LP acquired a new stake in shares of Sionna Therapeutics in the 1st quarter valued at approximately $1,465,000. Walleye Capital LLC bought a new stake in shares of Sionna Therapeutics during the 1st quarter valued at approximately $605,000. AlphaCentric Advisors LLC grew its holdings in shares of Sionna Therapeutics by 77.1% during the 1st quarter. AlphaCentric Advisors LLC now owns 4,818 shares of the company’s stock valued at $193,000 after purchasing an additional 2,098 shares during the last quarter. Finally, Jennison Associates LLC increased its position in Sionna Therapeutics by 30.1% during the 1st quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock worth $58,179,000 after purchasing an additional 335,942 shares in the last quarter.

Sionna Therapeutics Company Profile

(Get Free Report)

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.